Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Sophie Gray
Based on 2 articles published since 2009
(Why 2 articles?)
||||

Between 2009 and 2019, S. Gray wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Editorial HOX genes in pancreatic development and cancer. 2011

Gray, Sophie / Pandha, Hardev S / Michael, Agnieszka / Middleton, Gary / Morgan, Richard. · ·JOP · Pubmed #21546695.

ABSTRACT: The HOX genes are a family of homeodomain-containing transcription factors that determine cellular identity during development and which are subsequently re-expressed in many types of cancer. Some recent studies have shown that HOX genes may have key roles both in pancreatic development and in adult diseases of the pancreas, including cancer. In this review we consider recent advances in elucidating the role of HOX genes in these processes, how they may connect early developmental events to subsequent adult disease, and their potential both as diagnostic markers and therapeutic targets.

2 Review Targeting histone deacetylases for the treatment of immune, endocrine & metabolic disorders. 2009

Lawless, M W / Norris, S / O'Byrne, K J / Gray, S G. ·Department of Clinical Medicine, Trinity Centre for Health Sciences, Dublin, Ireland. ·Endocr Metab Immune Disord Drug Targets · Pubmed #19275684.

ABSTRACT: The 'histone code' is a well-established hypothesis describing the idea that specific patterns of post-translational modifications to histones act like a molecular "code" recognised and used by non-histone proteins to regulate specific chromatin functions. One modification which has received significant attention is that of histone acetylation. The enzymes which regulate this modification are described as histone acetyltransferases or HATs, and histone deacetylases or HDACs [1]. Due to their conserved catalytic domain HDACs have been actively targeted as a therapeutic target. The pro-inflammatory environment is increasingly being recognised as a critical element for both degenerative diseases and cancer. The present review will discuss the current knowledge surrounding the clinical potential & current development of histone deacetylases for the treatment of diseases for which a proinflammatory environment plays important roles, and the molecular mechanisms by which such inhibitors may play important functions in modulating the proinflammatory environment.